clinical-translational4

 

CEDOC Research

CEDOC - CHRONIC DISEASES RESEARCH CENTER - IS AN ESTABLISHED INSTITUTE WHICH AIMS AT EXCELLENCE IN MEDICAL RESEARCH ON CHRONIC DISEASES.

The general objectives of CEDOC are to form an internationally-recognized Center of excellence in Biomedical, Translational and Clinical Research on chronic diseases; to stimulate collaborative research between groups within the CEDOC; to strengthen research quality and innovation and to promote multidisciplinary projects within and beyond the Center; to provide an exciting research environment for the training of Postdoctoral Fellows, PhD and Master funding at national and international levels; and to simulate the organization of outreach activities at local and national levels.

Biomedical Research

CEDOC’s Biomedical research groups are multidisciplinary in nature, using existing knowledge from basic research and methodically expanding it to address a specific medical problem. The Biomedical Research they produce is oriented to understanding the causes of disease of various chronic pathologies, from diabetes and cancer to rare autoimmune diseases.

Research Groups

 
 

Biomedical Resources & Services

 
 

Clinical Research

CEDOC’s Clinical Research is conducted across the institute and its affiliated hospitals by Clinicians and Biomedical researchers. The main objective is to promote new therapeutic strategies, with considerable impact in public health.

Research Groups

 
 

Clinical Resources & Services

 
 

Research Units

CHRC

The Comprehensive Health Research Centre (CHRC) is a multidisciplinary, multi-institutional and comprehensive new research centre aimed at supporting, developing and fostering clinical, public health and health services research. The other CHRC pillars and central activities are health education and training; innovation, digital and entrepreneurship.

CHRC presentation video by CHRC Coordinator, Helena Canhão.
 

iNOVA4Health

iNOVA4Health is a translational medicine programme organizing the efforts of biomedical researchers involved in i) biological understanding of disease, lead compounds and biopharmaceuticals pre-discovery, ii) technological scientists involved in preclinical development, and iii) clinicians involved in early clinical and first-in-man clinical trials from institutions within NOVA University of Lisbon. The programme will have a strong emphasis on developing therapies to promote healthy ageing and in targeting chronic diseases that are responsible for two thirds of deaths worldwide and a major burden on healthcare systems